Kanabo Group Plc
("Kanabo" or the "Company")
Investor Webinar and Q&A
Kanabo Group plc (LSE:KNB) the pan-European medical cannabis company that focuses on developing and commercialising cannabis-derived products for medical patients and wellness CBD consumers, announces Avihu Tamir, Group CEO, and Suleman Sacranie, Founder of the GP Service, will provide an investor presentation relating to the Group's recently announced Unaudited Half Yearly results and updated strategy via Vox Markets on Thursday October 6th at 5.30PM.
The presentation is open to all existing and potential shareholders, subject to registration and will be followed by a Q&A session. Questions can be submitted ahead of the event to Kat Perez, kperez@voxmarkets.co.uk
To register for the presentation, please visit:
https://us02web.zoom.us/webinar/register/WN_kF4Gah7xTxuhUg7ZmppznQ
Those who follow Kanabo Group plc on the Vox Markets platform will receive a registration email.
For further information, please visit http://www.kanabogroup.com/ or contact the following:
| Kanabo Group Plc | Via Vox Markets |
| Avihu Tamir, CEO | |
| Peterhouse Capital Ltd (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Eran Zucker / Lauren Riley | |
| Peterhouse Capital Ltd (Corporate Broker) | Tel: +44 (0)20 7469 0930 |
| Lucy Williams / Charles Goodfellow / Duncan Vasey / Martin Lampshire | |
| Vox Markets (Investor Relations) | KanaboGroup@voxmarkets.co.uk |
| Kat Perez | kperez@voxmarkets.co.uk |
About Kanabo Group Plc
Kanabo Group Plc is a leading developer and distributer of cannabis-derived products and inhalation technologies for medical patients and non-THC products for CBD consumers. Kanabo Group Plc, which was the first medicinal cannabis company to complete an IPO on the London Stock Exchange, is a vertically integrated platform comprising cultivation consultancy, product R&D and formula development, and marketing and distribution. Its subsidiaries include:
· Kanabo Agritec Ltd, a cultivation consultancy supporting cannabis businesses in developing new farms through infrastructure, research, and product guidance. These farms deliver high-quality raw materials for Kanabo's formulas and product line.
· Kanabo Research Ltd, a wholly owned subsidiary of Kanabo Group Plc, responsible for R&D, regulation, and quality assurance procedures.
· The GP Service - a Kanabo Group Plc owned telehealth provider, offering NHS approved online consultations, online prescriptions, treatment forms and access to both Kanabo medical-cannabis & wellbeing CBD products.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
